Bioarchitech is an Oxford based biotech company developing immunotherapy for the treatment of cancer.
We engineer antibodies and other proteins then encode them within the genome of an oncoloytic virus. Cancer cells infected by our oncolytic virus release these potent immunotherapy molecules into the surrounding tumour microenvironment where they orchestrate the destruction of tumour cells by the patient’s own immune system.
The below time-lapse video shows one of our Bispecific T cell Engager (BiTE) molecules redirecting T cells to kill cancer cells.
Breast cancer cells (red) were co-cultured with T cells over a period of four days. No BiTE drug was added to the cells shown in the left panel and BiTE drug was added to the cells shown in the right panel. A green dye was added as a marker of cell death.